



Reverse Phase Protein Array (RPPA) Clinical Publications

Wulfkuhle JD, Yau C, Wolf DM, Vis DJ, Gallagher RI, Brown-Swigart L, Hirst G, Voest EE, DeMichele A, Hylton H, Symmans F, Yee DT, Esserman L, Berry D, Liu M, Park JW, Wessels L, van't Veer L, and Petricoin III, EF Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL JCO Precision Oncology 2018 :2, 1-20
<http://ascopubs.org/doi/10.1200/PO.18.00024>

Olshen A, Wolf D, Jones EF, Newitt D, Veer LV', Yau C, Esserman L, Wulfkuhle JD, Gallagher RI, Singer L, Petricoin EF 3rd, Hylton N, Park CC. Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham). 2018 Jan;5(1):011014.
<https://doi.org/10.1117/1.JMI.5.1.011014>

Einspahr JG, Curiel-Lewandrowski C, Calvert VS, Stratton SP, Alberts DS, Warneke J, Hu C, Saboda K, Wagener EL, Dickinson S, Dong Z, Bode AM, Petricoin III EF. Protein activation mapping of human sun-protected epidermis after an acute dose of erythemic solar simulated light. NPJ Precis Oncol. 2017; Epub Sep 21.
<https://www.nature.com/articles/s41698-017-0037-7>

Eke I, Makinde AY, Aryankalayil MJ, Sandfort V, Palayoor ST, Rath BH, Liotta L, Pierobon M, PetricoinEF, Brown MF, Stommel JM, Ahmed MM, Coleman CN. Exploiting radiation-induced signaling to increase the susceptibility of resistant cancer cells to targeted drugs: AKT and mTOR inhibitors as an example. Mol Cancer Ther. 2017 Aug 11.
<http://mct.aacrjournals.org/content/17/2/355>

Sereni MI, Baldelli E, Gambara G, Ravaggi A, Hodge KA, Alberts DS, Guillen-Rodriguez JM, Dong T, Memo M, Odicino F, Angioli R, Liotta LA, Pecorelli SL, Petricoin EF, Pierobon M. Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers. Br J Cancer. 2017 Aug 8;117(4):494-502.
<https://www.nature.com/articles/bjc2017195>

Pierobon M, Ramos C, Wong S, Hodge KA, Aldrich J, Byron SA, Anthony SP, Robert NJ, Northfelt DW, Jahanzeb M, Vocila L, Wulfkuhle JD, Gambara G, Gallagher RI, Dunetz B, Hoke N, Dong T, Craig DW, Cristofanilli M, Leyland Jones B, Liotta L, O'Shaughnessy JA, Carpten JD, Petricoin EF. Enrichment of PIK3-AKT-MTOR pathway activation in hepatic metastases from breast cancer. Clin Cancer Res. 2017 Apr 26. [Epub ahead of print]
<http://clincancerres.aacrjournals.org/content/23/16/4919.long>

Parasido EM, Silvestri A, Canzonieri V, Belluco C, Diodoro MG, Milione M, Melotti F, De Maria R, Liotta L, Petricoin EF, Pierobon M. Protein drug target activation homogeneity in the face of intra-tumor heterogeneity: implications for precision medicine. *Oncotarget*. 2016 Dec 15. doi: 10.18632/oncotarget.14019. [Epub ahead of print]
<https://doi.org/10.18632/oncotarget.14019>

Janda J, Burkett N, Blohm-Mangone K, Huang V, Curiel-Lewandrowski C, Alberts DS, Petricoin EF 3rd, Calvert VS, Einspahr J, Dong Z, Bode AM, Wondrak GT, Dickinson SE. Resatorvid-based Pharmacological Antagonism of Cutaneous TLR4 Blocks UV-induced NF- κ B and AP-1 Signaling in Keratinocytes and Mouse Skin. *Photochem Photobiol*. 2016 Nov 10.

<https://doi.org/10.1111/php.12659>

Pin E, Stratton S, Belluco C, Liotta L, Nagle R, Hodge KA, Deng J, Dong T, Baldelli E, Petricoin E, Pierobon M. A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray. *Mol Oncol*. 2016 Oct 14.

<https://febs.onlinelibrary.wiley.com/doi/full/10.1016/j.molonc.2016.09.007>

Bowie M, Pilie P, Wulfkuhle J, Lem S, Hoffman A, Desai S, Petricoin E, Carter A, Ambrose A, Seewaldt V, Yu D, Ibarra Drendall C. Fluoxetine induces cytotoxic endoplasmic reticulum stress and autophagy in triple negative breast cancer. *World J Clin Oncol*. 2015 Dec 10;6(6):299-311.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675916/>

Baldelli E, Bellezza G, Haura EB, Crinó L, Cress WD, Deng J, Ludovini V, Sidoni A, Schabath MB, Puma F, Vannucci J, Siggillino A, Liotta LA, Petricoin EF 3rd, Pierobon M. Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors. *Oncotarget*. 2015 Sep 30.

<https://doi.org/10.18632/oncotarget.5941>

Baldelli E, Haura EB, Crinò L, Cress WD, Ludovini V, Schabath MB, Liotta LA, Petricoin EF, Pierobon M. Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer: Implications for personalized medicine. *Proteomics Clin Appl*. 2015 Feb 11

<https://doi.org/10.1002/prca.201400056>

Sereni MI, Baldelli E, Gambara G, Zanotti L, Bandiera E, Bignotti E, Ragnoli M, Tognon G, Ravaggi A, Meani F, Memo M, Angioli R, Liotta LA, Pecorelli SL, Petricoin E 3rd, Pierobon M. Functional characterization of epithelial ovarian cancer histotypes by drug target-based protein signaling activation mapping: implications for personalized cancer therapy. *Proteomics*. 2015 Jan;15(2-3):365-73.

<https://doi.org/10.1002/pmic.201400214>

Jameson GS, Petricoin EF, Sachdev J, Liotta LA, Loesch DM, Anthony SP, Chadha MK, Wulfkuhle JD, Gallagher RI, Reeder KA, Pierobon M, Fulk MR, Cantafio NA, Dunetz B, Mikrut WD, Von Hoff DD, Robert NJ. A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer. *Breast Cancer Res Treat.* 2014 Oct;147(3):579-88.

<https://link.springer.com/article/10.1007%2Fs10549-014-3117-1>

Pierobon M, Silvestri A, Spira A, Reeder A, Pin E, Banks S, Parasido EM, Edmiston K, Liotta L, Petricoin E. A Pilot Phase I/II Personalized Therapy Trial For Metastatic Colorectal Cancer: Evaluating the Feasibility of Protein Pathway Activation Mapping For Stratifying Patients To Therapy With Imatinib And Panitumumab. *J Proteome Res.* 2014 May 1

<https://pubs.acs.org/doi/10.1021/pr401267m>

Bertacchini J, Guida M, Accordi B, Mediani L, Martelli AM, Barozzi P, Petricoin E 3rd, Liotta L, Milani G, Giordan M, Luppi M, Forghieri F, De Pol A, Cocco L, Basso G, Marmiroli S. Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in Acute Myeloid Leukemia revealed by pathway selective inhibition and phosphoproteome analysis. *Leukemia.* 2014 Apr 4. doi: 10.1038/leu.2014.123.

<https://www.nature.com/articles/leu2014123>

Cremona M, Espina V, Caccia D, Veneroni S, Colecchia M, Pierobon M, Deng J, Mueller C, Procopio G, Lanzi C, Daidone MG, Cho WC, Petricoin EF, Liotta L, Bongarzone I. Stratification of clear cell renal cell carcinoma by signaling pathway analysis. *Expert Rev Proteomics.* 2014 Feb 27

<https://doi.org/10.1586/14789450.2014.893193>

Mueller C, Decarvalho AC, Mikkelsen T, Lehman NL, Calvert V, Espina V, Liotta LA, Petricoin EF 3rd. Glioblastoma cell enrichment is critical for analysis of phosphorylated drug targets and proteomic-genomic correlations. *Cancer Res.* 2014 Feb 1;74(3):818-28

<http://cancerres.aacrjournals.org/content/74/3/818.long>

van der Veer A, van der Velden VH, Willemse ME, Hoogeveen PG, Petricoin EF, Beverloo HB, Escherich G, Horstmann MA, Pieters R, den Boer ML. Interference with pre-B-cell receptor signaling offers a therapeutic option for TCF3-rearranged childhood acute lymphoblastic leukemia. *Blood Cancer J.* 2014 Feb 14;4:e181.

<https://www.nature.com/articles/bcj20145>

Robertson FM, Petricoin III EF, Van Laere SJ, Bertucci F, Chu K, Fernandez SV, Mu Z, Alpaugh K, Pei J, Circo R, Wulfkuhle J, Ye Z, Boley KM, Liu H, Moraes R, Zhang X, Demaria R, Barsky SH, Sun G, Cristofanilli M. Presence of anaplastic lymphoma kinase in inflammatory breast cancer. *Springerplus.* 2013 Oct 1;2:497.

<https://doi.org/10.1186/2193-1801-2-497>

Xia W, Petricoin EF 3rd, Zhao S, Liu L, Osada T, Cheng Q, Wulfkuhle JD, Gwin WR, Yang X, Gallagher RI, Bacus S, Lyerly HK, Spector NL. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models. *Breast Cancer Res.* 2013 Sep 18;15(5):R85.

<https://doi.org/10.1186/bcr3480>

Wilson B, Liotta LA, Petricoin EF. Dynamic protein pathway activation mapping of adipose-derived stem cell differentiation implicates novel regulators of adipocyte differentiation. *Mol Cell Proteomics.* 2013;12: 2522-2535.

<https://doi.org/10.1074/mcp.M112.025346>

Hricik T, Federici G, Zeuner A, Alimena G, Tafuri A, Tirelli V, Varricchio L, Masiello F, Ciaffoni F, Vaglio S, Petricoin EF, Girelli G, Levine RL, Migliaccio AR. Transcriptomic and phospho-proteomic analyses of erythroblasts expanded in vitro from normal donors and from patients with polycythemia vera. *Am J Hematol.* 2013 May 29

<https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.23487>

Silvestri A, Pin E, Huijbers A, Pellicani R, Parasido EM, Pierobon M, Petricoin E, Liotta L, Belluco C. Individualized therapy for metastatic colorectal cancer. *J Intern Med.* 2013 Mar 26

<https://doi.org/10.1111/jiom.12070>

Chiechi A, Novello C, Magagnoli G, Petricoin EF 3rd, Deng J, Benassi MS, Picci P, Vaisman II, Espina V, Liotta LA. Elevated TNFR1 and Serotonin in bone metastasis are correlated with poor survival following bone metastasis diagnosis for both carcinoma and sarcoma primary tumors. *Clin Cancer Res.* 2013 Mar 14

<http://clincancerres.aacrjournals.org/content/19/9/2473.long>

Zupa A, Improta G, Silvestri A, Pin E, Deng J, Aieta M, Musto P, Nitti D, Mammano E, Liotta L, Belluco C, Wulfkuhle J, Petricoin E 3rd. A Pilot Characterization of Human Lung NSCLC by Protein Pathway Activation Mapping. *J Thorac Oncol.* 2012 Dec;7(12):1755-66.

<https://doi.org/10.1097/JTO.0b013e3182725fc7>

Silvestri A, Calvert V, Belluco C, Lipsky M, De Maria R, Deng J, Colombatti A, De Marchi F, Nitti D, Mammano E, Liotta L, Petricoin E, Pierobon M. Protein pathway activation mapping of colorectal metastatic progression reveals metastasis-specific network alterations. *Clin Exp Metastasis.* 2012 Sep 29. [Epub ahead of print]

<https://publicatt.unicatt.it/retrieve/handle/10807/111517/178227/Protein%20pathway%20activation%20mapping.pdf>

Wulfkuhle JD, Berg D, Wolff C, Langer R, Tran K, Illi J, Espina V, Pierobon M, Deng J, Demichele A, Walch A, Bronger H, Becker I, Waldhor C, Hofler H, Esserman LJ, Liotta LA, Becker KF, Petricoin EF 3rd. Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. *Clin Cancer Res.* 2012 Dec 1;18(23):6426-35.

<http://clincancerres.aacrjournals.org/content/18/23/6426.long>

Sirajuddin P, Das S, Ringer L, Rodriguez OC, Sivakumar A, Lee YC, Uren A, Fricke ST, Rood B, Ozcan A, Wang SS, Karam S, Yenugonda V, Salinas P, Petricoin E 3rd, Pishvaian M, Lisanti MP, Wang Y, Schlegel R, Moasser B, Albanese C. Quantifying the CDK inhibitor VMY-1-103's activity and tissue levels in an in vivo tumor model by LC-MS/MS and by MRI. *Cell Cycle.* 2012 Sep 14;11(20).

<https://doi.org/10.4161/cc.21988>

Hartsink-Segers SA, Zwaan CM, Exalto C, Luijendijk MW, Calvert VS, Petricoin EF, Evans WE, Reinhardt D, de Haas V, Hedtjärn M, Hansen BR, Koch T, Caron HN, Pieters R, Den Boer ML. Aurora kinases in childhood acute leukemia: the promise of Aurora B as therapeutic target. *Leukemia.* 2012 Sep 3. doi: 10.1038/leu.2012.256

<https://www.nature.com/articles/leu2012256>

Mammano E, Galdi F, Pierobon M, Tessari E, Deng J, Pucciarelli S, Agostini M, De Marchi F, Canzonieri V, De Paoli A, Belluco C, Liotta L, Petricoin E, Pilati P, Nitti D. Multiplexed Protein Signal Pathway Mapping Identifies Patients With Rectal Cancer That Responds to Neoadjuvant Treatment. *Clin Colorectal Cancer.* 2012 Jun 1

<https://dx.doi.org/10.1016%2Fj.clcc.2012.05.003>

Zuurbier L, Petricoin EF, Vuerhard MJ, Calvert V, Kooi C, Buijs-Gladdines J, Smits WK, Sonneveld E, Veerman AJ, Kamps WA, Horstmann M, Pieters R, Meijerink JP. The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia. *Haematologica.* 2012 Apr 4

<http://www.haematologica.org/content/97/9/1405.long>

Einspahr JG, Calvert V, Alberts DS, Curiel-Lewandrowski C, Warneke J, Krouse R, Stratton SP, Liotta L, Longo C, Pellicani G, Prasad A, Sagerman P, Bermudez Y, Deng J, Bowden GT, Petricoin EF 3rd. Functional protein pathway activation mapping of the progression of normal skin to squamous cell carcinoma. *Cancer Prev Res.* 2012 Mar;5(3):403-13

<https://dx.doi.org/10.1158%2F1940-6207.CAPR-11-0427>

Bose D, Zimmerman LJ, Pierobon M, Petricoin E, Tozzi F, Parikh A, Fan F, Dallas N, Xia L, Gaur P, Samuel S, Liebler DC, Ellis LM. Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells. *Br J Cancer.* 2011 Nov 1.

<https://www.nature.com/articles/bjc2011449>

Dey-Guha I, Wolfer A, Yeh AC, Albeck JG, Darp R, Leon E, Wulfkuhle J, Petricoin EF 3rd, Wittner BS, Ramaswamy S. Asymmetric cancer cell division regulated by AKT. *Proc Natl Acad Sci U S A.* 2011. Jul 14. [Epub ahead of print]

<https://doi.org/10.1073/pnas.1109632108>

Xia W, Liu Z, Zong R, Liu L, Zhao S, Bacus SS, Mao Y, He J, Wulfkuhle JD, Petricoin EF 3rd, Osada T, Yang XY, Hartman ZC, Clay TM, Blackwell KL, Lyerly HK, Spector NL. Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors. *Mol Cancer Ther.* 2011 Jun 14.
<http://mct.aacrjournals.org/content/10/8/1367.long>

Ibarra-Drendall C, Troch MM, Barry WT, Broadwater G, Petricoin EF 3rd, Wulfkuhle J, Liotta LA, Lem S, Baker JC Jr, Ford AC, Wilke LG, Zalles C, Kuderer NM, Hoffman AW, Shivraj M, Mehta P, Williams J, Tolbert N, Lee LW, Pilie PG, Yu D, Seewaldt VL. Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways. *Breast Cancer Res Treat.* 2011 Jun 7.

<https://link.springer.com/article/10.1007%2Fs10549-011-1609-9>

Improta G, Zupa A, Fillmore H, Deng J, Aieta M, Musto P, Liotta LA, Broaddus W, Petricoin EF, Wulfkuhle J. Protein Pathway Activation Mapping of Brain Metastasis from Lung and Breast Cancers Reveals Organ Type Specific Drug Target Activation. *J Proteome Res.* 2011 Jul 1;10(7):3089-97.

<https://doi.org/10.1021/pr200065t>

Fodale V, Pierobon M, Liotta L, Petricoin E. Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance? *Cancer J.* 2011 Mar-Apr;17(2):89-95.

<https://doi.org/10.1097/PPO.0b013e318212dd3d>

Frederick MJ, Vanmeter AJ, Gadhikar MA, Henderson YC, Yao H, Pickering CC, Williams MD, El-Naggar AK, Sandulache V, Tarco E, Myers JN, Clayman GL, Liotta LA, Petricoin EF 3rd, Calvert VS, Fodale V, Wang J, Weber RS. Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. *Am J Pathol.* 2011 Feb;178(2):548-71.

<https://dx.doi.org/10.1016%2Fajpath.2010.10.044>

Pilie PG, Ibarra-Drendall C, Troch MM, Broadwater G, Barry WT, Petricoin EF 3rd, Wulfkuhle JD, Liotta LA, Lem S, Baker JC Jr, Stouder A, Ford AC, Wilke LG, Zalles CM, Mehta P, Williams J, Shivraj M, Su Z, Geraerts J, Yu D, Seewaldt VL. Protein Microarray Analysis of Mammary Epithelial Cells from Obese and Non-Obese Women at High Risk for Breast Cancer: Feasibility Data. *Cancer Epidemiol Biomarkers Prev.* 2011 Jan 17.

<http://cebp.aacrjournals.org/content/20/3/476.long>

Younossi ZM, Limongi D, Stepanova M, Pierobon M, Afendy A, Mehta R, Baranova A, Liotta L, Petricoin E. Protein Pathway Activation Associated with Sustained Virologic Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon (PEG-IFN) and Ribavirin (RBV). *J Proteome Res.* 2011 Jan 4. [Epub ahead of print]

<https://pubs.acs.org/doi/abs/10.1021/pr100923u>

Maraldi T, Bertacchini J, Benincasa M, Guida M, De Pol A, Liotta LA, Petricoin E 3rd, Cocco L, Marmiroli S. Reverse-phase protein microarrays (RPPA) as a diagnostic and therapeutic guide in multidrug resistant leukemia. *Int J Oncol.* 2011 Feb;38(2):427-35.
<https://doi.org/10.3892/ijo.2010.850>

Matei D, Sill MW, Lankes HA, Degeest K, Bristow RE, Mutch D, Yamada SD, Cohn D, Calvert V, Farley J, Petricoin EF, Birrer MJ. Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial. *J Clin Oncol.* 2011 Jan 1;29(1):69-75.
<https://doi.org/10.1200/JCO.2009.26.7856>

Accordi B, Espina V, Giordan M, Vanmeter A, Milani G, Galla L, Ruzzene M, Sciro M, Trentin L, De Maria R, Te Kronnie G, Petricoin E, Liotta L, Basso G. Functional Protein Network Activation Mapping Reveals New Potential Molecular Drug Targets for Poor Prognosis Pediatric BCP-ALL. *PLoS One.* 2010 Oct 21;5(10)
<https://doi.org/10.1371/journal.pone.0013552>

Zuurbier L, Homminga I, Calvert V, Winkel MT, Buijs-Gladdines JG, Kooi C, Smits WK, Sonneveld E, Veerman AJ, Kamps WA, Horstmann M, Petricoin EF 3rd, Pieters R, Meijerink JP. NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. *Leukemia.* 2010 Dec;24(12):2014-22.
<https://doi.org/10.1038/leu.2010.204>

Espina V, Mariani BD, Gallagher RI, Tran K, Banks S, Wiedemann J, Huryk H, Mueller C, Adamo L, Deng J, Petricoin EF, Pastore L, Zaman S, Menezes G, Mize J, Johal J, Edmiston K, Liotta LA. Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival. *PLoS One.* 2010 Apr 20;5(4):e10240.
<https://doi.org/10.1371/journal.pone.0010240>

Silvestri A, Colombatti A, Calvert VS, Deng J, Mammano E, Belluco C, De Marchi F, Nitti D, Liotta LA, Petricoin EF, Pierobon M. Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing. *Lab Invest.* 2010 May;90(5):787-96.
<https://doi.org/10.1038/labinvest.2010.47>

Finley DS, Calvert VS, Inokuchi J, Lau A, Narula N, Petricoin EF, Zaldivar F, Santos R, Tyson DR, Ornstein DK. Periprostatic Adipose Tissue as a Modulator of Prostate Cancer Aggressiveness. *J Urol.* 2009 Oct;182(4):1621-7.
<https://doi.org/10.1016/j.juro.2009.06.015>

Pierobon M, Calvert V, Belluco C, Garaci E, Deng J, Lise M, Nitti D, Mammano E, Marchi FD, Liotta L, Petricoin E. Multiplexed Cell Signaling Analysis of Metastatic and Nonmetastatic Colorectal Cancer Reveals COX2-EGFR Signaling Activation as a Potential Prognostic Pathway Biomarker. *Clin Colorectal Cancer.* 2009 Apr;8(2):110-7.

<https://doi.org/10.3816/CCC.2009.n.018>

Gulmann C, Sheehan KM, Conroy RM, Wulfkuhle JD, Espina V, Mullarkey MJ, Kay EW, Liotta LA, Petricoin EF. Quantitative cell signalling analysis reveals down-regulation of MAPK pathway activation in colorectal cancer. *J Pathol.* 2009 Mar 20.

<https://doi.org/10.1002/path.2561>

Grubb R, Deng J, Pinto P, Mohler J, Chinnaiyan A, Rubin M, Linehan W, Liotta L, Petricoin EF, Wulfkuhle J. Pathway Biomarker Profiling of Localized and Metastatic Human Prostate Cancer Reveal Metastatic and Prognostic Signatures. *J Proteome Res.* 2009 Mar 10. [Epub ahead of print]

<https://doi.org/10.1021/pr8009337>

Vanmeter AJ, Rodriguez AS, Bowman ED, Harris CC, Deng J, Calvert VS, Silvestri A, Fredolini C, Chandhoke V, Petricoin EF 3rd, Liotta LA, Espina V. LCM and protein microarray analysis of human NSCLC: Differential EGFR phosphorylation events associated with mutated EGFR compared to wild type. *Mol Cell Proteomics.* 2008 Oct;7(10):1902-24.

<https://doi.org/10.1074/mcp.M800204-MCP200>

Espina VA, Edmiston KH, Heiby M, Pierobon M, Sciro M, Merritt B, Banks S, Deng J, Vanmeter AJ, Geho DH, Pastore L, Sennesh J, Petricoin EF 3rd, Liotta LA. A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. *Mol Cell Proteomics.* 2008 Oct;7(10):1998-2018.

<https://doi.org/10.1074/mcp.M700596-MCP200>

Wulfkuhle JD, Speer R, Pierobon M, Laird J, Espina V, Deng J, Mammano E, Yang SX, Swain SM, Nitti D, Esserman LJ, Belluco C, Liotta LA and Petricoin EF. Multiplexed Cell Signaling Analysis of Human Breast Cancer: Applications for Personalized Therapy. *J of Prot Res.* 2008 Apr;7(4):1508-17.

<https://doi.org/10.1021/pr7008127>

Espina V, Wulfkuhle JD, Calvert VS, Petricoin EF 3rd, Liotta LA. Reverse phase protein microarrays for monitoring biological responses. *Methods Mol Biol.* 2007;383:321-36.

https://doi.org/10.1007/978-1-59745-335-6_21

Zhou, J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, Margolick JB, Liotta LA, Petricoin EF, Zhang Y. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. *PNAS* 2007. Oct 9;104(41):16158-63.

<https://doi.org/10.1073/pnas.0702596104>

Sheehan KM, Gulmann, C, Eichler GS, Weinstein, J, Barrett HL, Kay EW, Conroy RM, Liotta LA, Petricoin EF, Signal Pathway Profiling of Epithelial and Stromal Compartments of Colonic Carcinoma Reveal Epithelial-Mesenchymal Transition *Oncogene*, 2007 10;27(3):323-31.

<https://doi.org/10.1038/sj.onc.1210647>

Petricoin EF, Espina V, Araujo RP, Midura B, Yeung C, Wan X, Eichler GS, Johann DJ, Qualman, S, Tsokos M, Krishnan K, Helman LJ, Liotta LA. Phosphoprotein Signal Pathway Mapping: Akt/mTOR Pathway Activation Association with Childhood Rhabdomyosarcoma Survival. *Cancer Research*. 2007;67(7):3431–4
<https://doi.org/10.1158/0008-5472.CAN-06-1344>

Calvert VS, Collantes R, Elariny H, Afendy A, Baranova A, Mendoza M, Goodman Z, Liotta LA, Petricoin EF, and Younossi ZM. A Systems Biology Approach to the Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD): Molecular Network Analysis of Human Adipose Tissue Can Distinguish Non-alcoholic Steatohepatitis (NASH) from Non-Progressive Simple Steatosis. *Hepatology*. 2007; 46(1): 166-172.
<https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.21688>

Do TV, Symowicz JC, Berman DM, Liotta LA, Petricoin EF 3rd, Stack MS, Fishman DA. Lysophosphatidic Acid down-regulates stress fibers and up-regulates pro-matrix metalloproteinase-2 activation in ovarian cancer cells. *Mol Cancer Res*. 2007 Feb;5(2):121-31
<https://doi.org/10.1158/1541-7786.MCR-06-0319>

Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, and Benz CC. Breast cancer growth prevention by statins. *Cancer Res*. 2006 Sep 1;66(17):8707-14.

<https://doi.org/10.1158/0008-5472.CAN-05-4061>

Gulmann C, Sheehan K, Kay E, Liotta L, Petricoin E 3rd. Array-based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer. *J Pathol*. 2006 Mar 3;208(5):595-606

<https://doi.org/10.1002/path.1958>

Gulmann C, Espina V, Petricoin E, Longo, DL, Santi M, Knutsen T, Raffeld M, Jaffe ES, Liotta LA, Feldman AL. Proteomic analysis of apoptotic pathways reveal prognostic factors in follicular lymphoma. *Clinical Cancer Research* 2005 Aug 15;11(16):5847-55.

<https://doi.org/10.1158/1078-0432.CCR-05-0637>

Belluco C, Mammano E, Petricoin E, Prevedello L, Calvert V, Liotta L, Nitti D, Lise M. Kinase substrate protein microarray analysis of human colon cancer and hepatic metastasis. *Clin Chim Acta*. 2005 May 24; [Epub ahead of print]

<https://doi.org/10.1016/j.cccn.2005.03.024>

Petricoin EF 3rd, Bichsel VE, Calvert VS, Espina V, Winters M, Young L, Belluco C, Trock BJ, Lippman M, Fishman DA, Sgroi DC, Munson PJ, Esserman LJ, Liotta LA. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. *J Clin Oncol*. 2005 May 20;23(15):3614-21.

<https://doi.org/10.1200/JCO.2005.02.509>

Winters ME, Mehta AI, Petricoin EF 3rd, Kohn EC, Liotta LA. Supra-additive growth inhibition by a celecoxib analogue and carboxyamido-triazole is primarily mediated through apoptosis. *Cancer Res.* 2005 May 1;65(9):3853-60

<https://doi.org/10.1158/0008-5472.CAN-04-1989>

Iyengar P, Espina V, Williams TW, Lin Y, Berry D, Jelicks LA, Lee H, Temple K, Graves R, Pollard J, Chopra N, Russell RG, Sasisekharan R, Trock BJ, Lippman M, Calvert VS, Petricoin EF, Liotta L, Dadachova E, Pestell RG, Lisanti MP, Bonaldo P, Scherer PE. Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. *J Clin Invest.* 2005 May 2;115(5):1163-1176.

<https://doi.org/10.1172/JCI23424>

Sheehan KM, Calvert VS, Kay EW, Lu Y, Fishman D, Espina V, Aquino J, Speer R, Araujo R, Mills GB, Liotta LA, Petricoin EF 3rd, Wulfkuhle JD. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. *Mol Cell Proteomics.* 2005 Apr;4(4):346-55. Epub 2005 Jan 25.

<https://doi.org/10.1074/mcp.T500003-MCP200>

Roberts E, Charboneau L, Espina V, Liotta L, Petricoin E, and Dreher K. Application of laser capture microdissection and protein microarray technologies in the molecular analysis of airway injury following pollution particle exposure. *J Toxicol Environ Health A.* 2004 Jun 11;67(11):851-61.

<https://doi.org/10.1080/15287390490425768>

Zha H, Raffeld M, Charboneau L, Pittaluga S, Kwak LW, Petricoin E, Liotta LA and Jaffe ES. Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. *J Lab Invest.* 2004 Feb;84(2):235-44.

<https://doi.org/10.1038/labinvest.3700051>

Espina V, Dettloff KA, Cowherd S, Petricoin 3rd EF, and Liotta LA. Use of proteomic analysis to monitor responses to biological therapies. *Expert Opin Biol Ther.* 2004 Jan;4(1):83-93.

<https://doi.org/10.1517/14712598.4.1.83>

Grubb RL, Calvert VS, Paweletz CP, Phillips JL, Linehan WM, Gillespie JW, Emmert-Buck MR, Liotta L, and Petricoin EF. Signal pathway profiling of prostate cancer using reverse phase protein arrays. *Proteomics*. 2003 Nov;3(11):2142-6.

<https://doi.org/10.1002/pmic.200300598>

Wulfkuhle JD., Aquino JA, Calvert VS, Fishman DA, Coukos G, Liotta LA, and Petricoin EF. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase microarrays. *Proteomics*. 2003 Nov;3(11):2085-90.

<https://doi.org/10.1002/pmic.200300591>

Nishizuka S, Charboneau L, Young L, Major S, Reinhold WC, Waltham M, Kourou-Mehr H, Bussey KJ, Lee JK, Munson PJ, Petricoin EF, Liotta LA, and Weinstein JN. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: Identification by genomic, proteomic, and tissue array profiling. *Cancer Research*. 2003 Sep 1;63(17):5243-50.

<http://cancerres.aacrjournals.org/content/63/17/5243.long>

Herrmann PC, Gillespie JW, Charboneau L, Bichsel VE, Paweletz CP, Calvert VS, Kohn EC, Emmert-Buck MR, Liotta LA, and Petricoin EF. Mitochondrial proteome: Altered cytochrome c oxidase subunit levels in prostate cancer. *Proteomics*. 2003 Sep;3(9):1801-10.

<https://doi.org/10.1002/pmic.200300461>

Jones MB, Michener CM, Blanchette JO, Kuznetsov VA, Raffeld M, Serrero G, Emmert-Buck MR, Petricoin EF, Krizman DB, Liotta LA, and Kohn EC. The granulin-epithelin precursor/PC-Cell-derived growth factor is a growth factor for epithelial ovarian cancer. *Clin Cancer Res*. 2003 Jan;9(1):44-51.

<http://clincancerres.aacrjournals.org/content/9/1/44.long>

Wulfkuhle JD, Sgroi DC, Krutzsch H, McLean K, McGarvey K, Knowlton M, Chen S, Shu H, Sahin A, Kurek R, Wallwiener D, Merino MJ, Petricoin EF 3rd, Zhao Y, and Steeg PS. Proteomics of human breast ductal carcinoma in situ. *Cancer Res*. 2002 Nov 15; 62(22):6740-9.

<http://cancerres.aacrjournals.org/content/62/22/6740.long>

Ahram M, Best C, Flraig M, Gillespie J, Leiva I, Chuaqui R, Zhou G, Shu H, Duray P, Linehan W, Raffeld M, Ornstein D, Zhao Y, Petricoin EF, and Emmert-Buck MR. Proteomic analysis of human prostate cancer. *Mol Carcinogenesis*. 2002 Jan;33(1):9-15.

<https://onlinelibrary.wiley.com/doi/abs/10.1002/mc.10019>

Wulfkuhle JD, McLean KC, Paweletz CP, Sgroi DC, Trock BJ, Steeg PS, and Petricoin EF 3rd. New approaches to proteomic analysis of breast cancer. *Proteomics*. 2001 Oct;1(10):1205-15.

[https://doi.org/10.1002/1615-9861\(200110\)1:10%3C1205::AID-PROT1205%3E3.0.CO;2-X](https://doi.org/10.1002/1615-9861(200110)1:10%3C1205::AID-PROT1205%3E3.0.CO;2-X)

Paweletz CP, Charboneau L, Roth MJ, Bichsel VE, Simone NL, Chen T, Han N, Gillespie JW, Emmert-Buck M, Petricoin EF, and Liotta LA. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. *Oncogene*. 2001 Apr 12;20(16):1981-9.

<https://doi.org/10.1038/sj.onc.1204265>

Reverse Phase Protein Array (RPPA) Research Publications

Pierobon M, Petricoin EF 3rd, Wulfkuhle JD. Phosphoprotein-based drug target activation mapping for precision oncology: a view to the future. *Expert Rev Proteomics.* 2018 Oct 10:1-3.

<https://doi.org/10.1080/14789450.2018.1531709>

Cruickshanks N, Zhang Y, Hine S, Gibert M, Yuan F, Oxford M, Grello CM, Pahuski M, Dube C, Guessous F, Wang B, Deveau C, Saoud K, Gallagher RI, Wulfkuhle JD, Schiff D, Phan SC, Petricoin EF, Abounader R. Discovery and therapeutic exploitation of mechanisms of resistance to MET inhibitors in glioblastoma. *Clin Cancer Res.* 2018 Sep 10.

<https://doi.org/10.1158/1078-0432.CCR-18-0926>

deCarvalho AC, Kim H, Poisson LM, Winn ME, Mueller C, Cherba D, Koeman J, Seth S, Protopopov A, Felicella M, Zheng S, Multani A, Jiang Y, Zhang J, Nam DH, Petricoin EF, Chin L, Mikkelsen T, Verhaak RGW. Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma. *Nat Genet.* 2018 Apr 23.

<https://doi.org/10.1038/s41588-018-0105-0>

Pollmann SE, Calvert VS, Rao S, Boca SM, Madhavan S, Horak ID, Kjaer A, Petricoin EF, Kragh M, Poulsen TT. Acquired resistance to a MET antibody *in vivo* can be overcome by the MET antibody mixture Sym015. *Mol Cancer Ther.* 2018 Mar 15.

<https://doi.org/10.1158/1535-7163.MCT-17-0787>

Blohm-Mangone K, Burkett NB, Tahsin S, Myrdal PB, Aodah A, Ho B, Janda J, McComas M, Saboda K, Roe DJ, Dong Z, Bode AM, Petricoin EF, Calvert VS, Curiel-Lewandrowski C, Alberts DS, Wondrak GT, Dickinson SE. Pharmacological TLR4 antagonism using topical resatorvid blocks solar UV-induced skin tumorigenesis in SKH-1 mice. *Cancer Prev Res.* 2018 Feb 1.

<https://doi.org/10.1158/1940-6207.CAPR-17-0349>

de la Fuente C, Pinkham C, Dabbagh D, Beitzel B, Garrison A, Palacios G, Hodge KA, Petricoin EF, Schmaljohn C, Campbell CE, Narayanan A, Kehn-Hall K. Phosphoproteomic analysis reveals Smad protein family activation following Rift Valley fever virus infection. *PLoS One.* 2018 Feb 6;13(2).

<https://doi.org/10.1371/journal.pone.0191983>

Ding KF, Petricoin EF, Finlay D, Yin H, Hendricks WPD, Sereduk C, Kiefer J, Sekulic A, LoRusso PM, Vuori K, Trent JM, Schork NJ. Nonlinear mixed effects dose response modeling in high throughput drug screens: application to melanoma cell line analysis. *Oncotarget.* 2017 Dec 15;9(4):5044-5057.

<https://doi.org/10.18632/oncotarget.23495>

Tricoli L, Naeem A, Parasido E, Mikhail JP, Choudhry MU, Berry DL, Abdelgawad IA, Lee RJ, Feldman AS, Ihemelandu C, Avantaggiati M, Kumar D, Byers S, Gallagher R, Wulfkuhle J, Petricoin E, Rodriguez O, Albanese C. Characterization of the effects of defined, multidimensional culture conditions on conditionally reprogrammed primary human prostate cells. *Oncotarget*. 2017 Dec 18;9(2):2193-2207.

<https://doi.org/10.18632/oncotarget.23363>

Ludovini V, Chiari R, Tomassoni L, Antonini C, Baldelli E, Baglivo S, Siggillino A, Tofanetti FR, Bellezza G, Hodge KA, Petricoin E, Pierobon M, Crinò L, Bianconi F. Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study. *Oncotarget*. 2017 Jun 14;8(47):83343-83353.

<https://doi.org/10.18632/oncotarget.18480>

Guo Z, Sevrioukova IF, Denisov IG, Zhang X, Chiu TL, Thomas DG, Hanse EA, Cuellar RAD, Grinkova YV, Langenfeld VW, Swedien DS, Stamschror JD, Alvarez J, Luna F, Galván A, Bae YK, Wulfkuhle JD, Gallagher RI, Petricoin EF 3Rd, Norris B, Flory CM, Schumacher RJ, O'Sullivan MG, Cao Q, Chu H, Lipscomb JD, Atkins WM, Gupta K, Kelekar A, Blair IA, Capdevila JH, Falck JR, Sligar SG, Poulos TL, Georg GI, Ambrose E, Potter DA. Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria. *Cell Chem Biol*. 2017 Oct 19;24(10):1314.

<https://doi.org/10.1016/j.chembiol.2017.08.009>

Jayappa KD, Portell CA, Gordon VL, Capaldo BJ, Bekiranov S, Axelrod MJ, Brett LK, Wulfkuhle JD, Gallagher RI, Petricoin EF, Bender TP, Williams ME, Weber MJ. Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. *Blood Adv*. 2017 Jun 13;1(14):933-946.

<https://dx.doi.org/10.1182%2Fbloodadvances.2016004176>

Rao G, Pierobon M, Kim IK, Hsu WH, Deng J, Moon YW, Petricoin EF, Zhang YW, Wang Y, Giaccone G. Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations. *Sci Rep*. 2017 Aug 1;7(1):7066.

<https://doi.org/10.1038/s41598-017-06128-9>

Varghese RS, Zuo Y, Zhao Y, Zhang YW, Jablonski SA, Pierobon M, Petricoin EF, Ressom HW, Weiner LM. Protein network construction using reverse phase protein array data. *Methods*. 2017 Jul 15;124:89-99

<https://doi.org/10.1016/j.ymeth.2017.06.017>

Zhang Y, Cruickshanks N, Yuan F, Wang B, Pahuski M, Wulfkuhle J, Gallagher I, Koeppel AF, Hatef S, Papanicolias C, Lee J, Bar EE, Schiff D, Turner S, Petricoin EF, Gray LS, Abounader R. Targetable T-type calcium channels drive glioblastoma. *Cancer Res*. 2017 May 16.

<https://doi.org/10.1158/0008-5472.CAN-16-2347>

Gordon MA, D'Amato NC, Gu H, Babbs B, Wulfkuhle JD, Petricoin EF, Gallagher I, Dong T, Torkko K, Liu B, Elias A, Richer JK. Synergy between androgen receptor antagonism and inhibition of mTOR and HER2 in breast cancer. *Mol Cancer Ther.* 2017 May 3. [Epub ahead of print]

<https://doi.org/10.1158/1535-7163.MCT-17-0111>

Simbulan-Rosenthal CM, Dakshanamurthy S, Gaur A, Chen YS, Fang HB, Abdussamad M, Zhou H, Zapas J, Calvert V, Petricoin EF, Atkins MB, Byers SW, Rosenthal DS. The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma. *Oncotarget.* 2017 Feb 2. doi: 10.18632/oncotarget.14990. [Epub ahead of print]

<https://doi.org/10.18632/oncotarget.14990>

Brody JR, Yabar CS, Zarei M, Bender J, Matrisian LM, Rahib L, Heartwell C, Mason K, Yeo CJ, Peiper SC, Jiang W, Varieur K, Madhavan S, Petricoin E 3rd, Fortuna D, Curtis M, Wang ZX, Pishvaian MJ, Winter JM. Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer. *Cancer Biol Ther.* 2016 Jul 28:0.

<https://doi.org/10.1080/15384047.2016.1210743>

Dickinson SE, Janda J, Criswell J, Blohm-Mangone K, Olson ER, Liu Z, Barber C, Rusche JJ, Petricoin E 3rd, Calvert V, Einspahr JG, Dickinson JE, Stratton SP, Curiel-Lewandrowski C, Saboda K, Hu C, Bode AM, Dong Z, Alberts DS, Bowden GT. Inhibition of Akt Enhances the Chemopreventive Effects of Topical Rapamycin in Mouse Skin. *Cancer Prev Res.* 2016 2016 Mar;9(3):215-24

<https://doi.org/10.1158/1940-6207.CAPR-15-0419>

Hayes TK, Neel NF, Hu C, Gautam P, Chenard M, Long B, Aziz M, Kassner M, Bryant KL, Pierobon M, Marayati R, Kher S, George SD, Xu M, Wang-Gillam A, Samatar AA, Maitra A, Wennerberg K, Petricoin EF 3rd, Yin HH, Nelkin B, Cox AD, Yeh JJ, Der CJ. Long-term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. *Cancer Cell.* 2016 Jan 11;29(1):75-89

<https://doi.org/10.1016/j.ccr.2015.11.011>

Roller DG, Capaldo B, Bekiranov S, Mackey AJ, Conaway MR, Petricoin EF, Gioeli D, Weber MJ. Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas. *Oncotarget.* 2015 Dec 10.

<https://doi.org/10.18632/oncotarget.6548>

Budd WT, Seashols-Williams SJ, Clark GC, Weaver D, Calvert V, Petricoin E, Dragoescu EA, O'Hanlon K, Zehner ZE. Dual Action of miR-125b As a Tumor Suppressor and OncomiR-22 Promotes Prostate Cancer Tumorigenesis. *PLoS One.* 2015 Nov 6;10(11).

<https://doi.org/10.1371/journal.pone.0142373>

Capaldo BJ, Roller D, Axelrod MJ, Koeppel AF, Petricoin EF, Slingluff CL Jr, Weber MJ, Mackey AJ, Gioeli D, Bekiranov S. Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma. *PLoS One*. 2015 Sep 25;10(9):e0138210.

<https://doi.org/10.1371/journal.pone.0138210>

Blanco FF, Jimbo M, Wulfkuhle J, Gallagher I, Deng J, Enyenihi L, Meisner-Kober N, Londin E, Rigoutsos I, Sawicki JA, Risbud MV, Witkiewicz AK, McCue PA, Jiang W, Rui H, Yeo CJ, Petricoin E, Winter JM, Brody JR. The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells. *Oncogene*. 2015 Sep 21. doi: 10.1038/onc.2015.325.

<https://doi.org/10.1038/onc.2015.325>

LeBlanc FR, Liu X, Hengst J, Fox T, Calvert V, Petricoin EF 3rd, Yun J, Feith DJ, Loughran TP Jr. Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia. *Cancer Biol Ther*. 2015 Aug 7:0. [Epub ahead of print]

<https://doi.org/10.1080/15384047.2015.1078949>

Zhang YW, Nasto RE, Varghese R, Jablonski SA, Serebriiskii IG, Surana R, Calvert VS, Bebu I, Murray J, Jin L, Johnson M, Riggins R, Ressom H, Petricoin E, Clarke R, Golemis EA, Weiner LM. Acquisition of estrogen independence induces TOB1-related mechanisms supporting breast cancer cell proliferation. *Oncogene*. 2015 Jul 13. doi: 10.1038/onc.2015.226.

<https://doi.org/10.1038/onc.2015.226>

Bermudez Y, Stratton SP, Curiel-Lewandrowski C, Warneke JA, Hu C, Bowden GT, Dickinson SE, Dong Z, Bode AM, Saboda K, Brooks C, Petricoin E 3rd, Hurst C, Alberts DS, Einspahr JG. Activation of the PI3K/Akt/mTOR and MAP kinase Signaling Pathways in Response to Acute Solar Simulated Light Exposure of Human Skin. *Cancer Prev Res* 2015 Aug;8(8):720-8

<https://dx.doi.org/10.1158%2F1940-6207.CAPR-14-0407>

Alem F, Yao K, Lane D, Calvert V, Petricoin EF, Kramer L, Hale ML, Bavari S, Panchal RG, Hakami RM. Host response during *Yersinia pestis* infection of human bronchial epithelial cells involves negative regulation of autophagy and suggests a modulation of survival-related and cellular growth pathways. *Front Microbiol*. 2015 Feb 13;6:50

<https://doi.org/10.3389/fmicb.2015.00050>

Ligaba SB, Khurana A, Graham G, Krawczyk E, Jablonski S, Petricoin EF, Glazer RI, Upadhyay G. Multifactorial analysis of conditional reprogramming of human keratinocytes. *PLoS One*. 2015 Feb 25;10(2)

<https://doi.org/10.1371/journal.pone.0116755>

Falchi M, Varricchio L, Martelli F, Masiello F, Federici G, Zingariello M, Girelli G, Whitsett C, Petricoin EF, Moestrup SK, Zeuner A, Migliaccio AR. Dexamethasone targeted directly to macrophages induces macrophage niches that promote erythroid expansion. *Haematologica*. 2014 Dec 22.

<https://doi.org/10.3324/haematol.2014.114405>

Tian Y, Wang SS, Zhang Z, Rodriguez OC, Petricoin E 3rd, Shih IM, Chan D, Avantaggiati M, Yu G, Ye S, Clarke R, Wang C, Zhang B, Wang Y, Albanese C. Integration of network biology and imaging to study cancer phenotypes and responses. *IEEE/ACM Trans Comput Biol Bioinform*. 2014 Nov-Dec;11(6):1009-1019.

<https://dx.doi.org/10.1109%2FTCBB.2014.2338304>

Voss K, Amaya M, Mueller C, Roberts B, Kehn-Hall K, Bailey C, Petricoin E 3rd, Narayanan A. Inhibition of host extracellular signal-regulated kinase (ERK) activation decreases new world alphavirus multiplication in infected cells. *Virology*. 2014 Sep 24;468-470C:490-503.

<https://doi.org/10.1016/j.virol.2014.09.005>

Mikkelsen T, deCarvalho AC, Arnold K, Mueller C, Petricoin EF 3rd, Poisson LM, Irtenkauf S, Hasselbach L. Cabozantinib is effective in a subset of xenograft gbm tumors and affects multiple signaling pathways. *Neuro Oncol*. 2014 Jul;16 Suppl 3:iii38. <https://dx.doi.org/10.1093%2Fneuonc%2Fnou208.58>

Signore M, Pelacchi F, di Martino S, Runci D, Biffoni M, Giannetti S, Morgante L, De Majo M, Petricoin EF, Stancato L, Larocca LM, De Maria R, Pallini R, Ricci-Vitiani L. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo. *Cell Death Dis*. 2014 May 8;5:e1223.

<https://doi.org/10.1038/cddis.2014.188>

Liotta LA, Petricoin EF 3rd. Multiplex Proteomic Analysis of Cells in Fine Needle Aspiration Specimens: How Soon Can We Expect to Individualize Therapy by Comparing Pre- and Posttreatment Biopsies? *Clin Chem*. 2014 Apr 9.

<http://clinchem.aaccjnl.org/content/60/9/1143>

Amaya M, Voss K, Sampey G, Senina S, de la Fuente C, Mueller C, Calvert V, Kehn-Hall K, Carpenter C, Kashanchi F, Bailey C, Mogelsvang S, Petricoin E, Narayanan A. The Role of IKK β in Venezuelan Equine Encephalitis Virus Infection. *PLoS One*. 2014 Feb 19;9(2):e86745.

<https://doi.org/10.1371/journal.pone.0086745>

Salhia B, Kiefer J, Ross JT, Metapally R, Martinez RA, Johnson KN, Diperna DM, Paquette KM, Jung S, Nasser S, Wallstrom G, Tembe W, Baker A, Carpten J, Resau J, Ryken T, Sibenaller Z, Petricoin EF, Liotta LA, Ramanathan RK, Berens ME, Tran NL.

Integrated genomic and epigenomic analysis of breast cancer brain metastasis. PLoS One. 2014 Jan 29;9(1):e85448.

<https://doi.org/10.1371/journal.pone.0085448>

Lai C-H, Park K-S, Lee D-H, Alberobello AT, Raffeld M, Pierobon M, Pin E, Petricoin EF, Wang Y, Giaccone G. 2014. HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer. Oncogene. 2013 Oct 28. doi: 10.1038/onc.2013.439.

<https://doi.org/10.1038/onc.2013.439>

Federici G, Gao X, Slawek J, Arodz T, Shitaye A, Wulfkuhle JD, De Maria R, Liotta LA, Petricoin EF 3rd. Systems Analysis Of The Nci-60 Cancer Cell Lines By Alignment Of Protein Pathway Activation Modules With "-Omic" Data Fields And Therapeutic Response Signatures. Mol Cancer Res. 2013 May 1.

<https://doi.org/10.1158/1541-7786.MCR-12-0690>

Zhang Y, Farenholtz K, Yang Y, Guessous F, Dipierro CG, Calvert V, Deng J, Schiff D, Xin W, Lee J, Purow BW, Christensen JG, Petricoin EF 3rd, Abounader R. Hepatocyte growth factor sensitizes brain tumors to c-Met kinase inhibition. Clin Cancer Res. 2013 Feb 5.

<https://doi.org/10.1158/1078-0432.CCR-12-2832>

Godinho MF, Wulfkuhle JD, Look MP, Siewerts AM, Sleijfer S, Foekens JA, Petricoin EF 3rd, Dorssers LC, van Agthoven T. BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib. Br J Cancer. 2012 Aug 14. doi:10.1038/bjc.2012.351.

<https://doi.org/10.1038/bjc.2012.351>

van Agthoven T, Godinho MF, Wulfkuhle JD, Petricoin EF 3rd, Dorssers LC. Protein pathway activation mapping reveals molecular networks associated with anti-estrogen resistance in breast cancer cell lines. Int J Cancer. 2012 Feb 1

<https://doi.org/10.1002/ijc.27489>

Goudarzi M, Ross MM, Zhou W, Van Meter A, Deng J, Martin LM, Martin C, Liotta L, Petricoin E, Ad N Development of a Novel Proteomic Approach for Mitochondrial Proteomics from Cardiac Tissue from Patients with Atrial Fibrillation. J Proteome Res. 2011 Jul 8.

<https://pubs.acs.org/doi/abs/10.1021/pr200108m>

Gioeli D, Wunderlich W, Sebolt-Leopold J, Bekiranov S, Wulfkuhle JD, Petricoin EF 3rd, Conaway MR, Weber MJ. Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration resistant prostate cancer. Mol Cancer Ther. 2011 Jun 28.

<https://doi.org/10.1158/1535-7163.MCT-10-1033>

Popova TG, Narayanan A, Lance Liotta L Petricoin E F III, Bailey C, Kehn-Hall K, and Kashanchi F Reverse-phase phosphoproteome analysis (RPMA) of signaling pathways induced by HTLV-1 infection Retrovirology 2011, 8(Suppl 1)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112650/?report=reader>

Anderson T, Wulfkuhle J, Petricoin E, Winslow RL. High resolution mapping of the cardiac transmural proteome using reverse phase protein microarrays. Mol Cell Proteomics. 2011 Apr 13. [Epub ahead of print]

<https://dx.doi.org/10.1016%2Fj.molonc.2010.09.003>

Popova TG, Turell MJ, Espina V, Kehn-Hall K, Kidd J, Narayanan A, Liotta L, Petricoin EF, Kashanchi F, Bailey C, Popov SG. Reverse-phase phosphoproteome analysis of signaling pathways induced by rift valley Fever virus in human small airway epithelial cells. PLoS One. 2010 Nov 3;5(11):e13805.

<https://doi.org/10.1371/journal.pone.0013805>

Wilson B, Liotta LA, Petricoin E 3rd. Monitoring proteins and protein networks using reverse phase protein arrays. Dis Markers. 2010;28(4):225-32.

<https://doi.org/10.3233/DMA-2010-0705>

Younossi Z, Baranova A, Stepanova M, Page S, Calvert V, Afendy A, Goodman Z, Chandhoke V, Liotta L, Petricoin E. Phosphoproteomics Biomarkers Predicting Non-alcoholic Steatohepatitis and Fibrosis. J Proteome Res. 2010 May 4.

<https://pubs.acs.org/doi/abs/10.1021/pr100069e>

Popova T, Espina VE, Bailey C, Liotta L, Petricoin E, Popov S. Anthrax infection inhibits the AKT signaling involved in the E-cadherin-mediated adhesion of lung epithelial cells FEMS Immunol Med Microbiol. 2009 April E pub ahead of print

<http://images.biomedsearch.com/19416348/fim0056-0129.pdf?AWSAccessKeyId=AKIAIBOKHYOLP4MBMRGQ&Expires=1545177600&Signature=wQyTQV5aMqDIGieJX40d5bwvusk%3D>

Shankavaram UT, Reinhold WC, Nishizuka S, Major S, Morita D, Chary KK, Reimers MA, Scherf U, Kahn A, Dolginow D, Cossman J, Kaldjian EP, Scudiero DA, Petricoin E, Liotta L, Lee JK, Weinstein JN. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther. 2007 Mar;6(3):820-32

<https://doi.org/10.1158/1535-7163.MCT-06-0650>

Woodhouse EC, Fisher A, Bandle RW, Bryant-Greenwood B, Charboneau L, Petricoin EF 3rd, and Liotta LA. Drosophila screening model for metastasis: Semaphorin 5c is required for I(2)gl cancer phenotype. Proc Natl Acad Sci. 2003 Sep 30;100(20):11463-8.

<https://doi.org/10.1073/pnas.2031202100>

Nishizuka S, Charboneau L, Young L, Major S, Reinhold WC, Waltham M, Kouros-Mehr H, Bussey KL, Lee JK, Munson PJ, Petricoin III EF, Liotta LA, and Weinstein JN. Proteomic profiling of the NCI60 cancer cell lines using new high-density 'reverse-phase' lysate microarrays. Proc. Natl Acad Sci. 2003 Nov 25;100(24):14229-34.
<https://doi.org/10.1073/pnas.2331323100>

Reverse Phase Protein Array (RPPA) Technical Publications

Baldelli E, Calvert V, Hodge A, VanMeter A, Petricoin EF 3rd, Pierobon M. Reverse Phase Protein Microarrays. *Methods Mol Biol.* 2017;1606:149-169.

https://doi.org/10.1007/978-1-4939-6990-6_11

Wulfkuhle JD, Spira A, Edmiston KH, Petricoin EF 3rd. Innovations in Clinical Trial Design in the Era of Molecular Profiling. *Methods Mol Biol.* 2017;1606:19-36.

https://doi.org/10.1007/978-1-4939-6990-6_2

Akbani R, Baker KF, Carragher N, Goldstein T, de Koning L, Korf U, Liotta LA, Mills GB, Nishizuka SS, Petricoin EF, Pollard HB, Serrels B, Zhu J. Realizing the promise of reverse phase protein arrays for clinical, translational and basic research : a workshop report. *Mol Cell Proteomics.* 2014 Apr 28. [Epub ahead of print]

<https://doi.org/10.1074/mcp.O113.034918>

Pierobon M, Wulfkuhle J, Liotta L, Petricoin E. Application of molecular technologies for phosphoproteomic analysis of clinical samples. *Oncogene.* 2014 Mar 10. doi:

10.1038/onc.2014.16

<https://doi.org/10.1038/onc.2014.16>

Pin E, Federici G, Petricoin EF 3rd. Preparation and use of reverse protein microarrays. *Curr Protoc Protein Sci.* 2014 Feb 3;75:27.7.1-27.7.29

<https://doi.org/10.1002/0471140864.ps2707s75>

Sereni MI, Pierobon M, Angioli R, Petricoin EF 3rd, Frederick MJ. Reverse phase protein microarrays and their utility in drug development. *Methods Mol Biol.* 2013;986:187-214.

https://doi.org/10.1007/978-1-62703-311-4_13

Pierobon M, Vanmeter AJ, Moroni N, Galdi F, Petricoin EF 3rd. Reverse-phase protein microarrays. *Methods Mol Biol.* 2012;823:215-35.

https://doi.org/10.1007/978-1-60327-216-2_14

Gallagher RI, Silvestri A, Petricoin EF 3rd, Liotta LA, Espina V. Reverse phase protein microarrays: fluorometric and colorimetric detection. *Methods Mol Biol.* 2011;723:275-301.

https://doi.org/10.1007/978-1-61779-043-0_18

Pierobon M, Belluco C, Liotta LA, Petricoin EF 3rd. Reverse phase protein microarrays for clinical applications. *Methods Mol Biol.* 2011;785:3-12.

https://doi.org/10.1007/978-1-61779-286-1_1

Anderson T, Wulfkuhle J, Liotta L, Winslow RL, Petricoin E 3rd. Improved reproducibility of reverse phase protein microarrays using array microenvironment normalization. *Proteomics.* 2009 Dec;9(24):5562-6.

<https://doi.org/10.1002/pmic.200900505>

Espina V, Liotta LA, Petricoin EF. Reverse-phase protein microarrays for theranostics and patient tailored therapy. *Methods Mol Biol.* 2009;520:89-105.
https://doi.org/10.1007/978-1-60327-811-9_7

Nijdam AJ, Zianni MR, Herderick EE, Cheng MM, Prosperi JR, Robertson FA, Petricoin EF, Liotta LA, Ferrari M Application of Physicochemically Modified Silicon Substrates as Reverse-Phase Protein Microarrays. *J Proteome Res.* 2009 Jan 26.
<https://pubs.acs.org/doi/abs/10.1021/pr800455y>

Speer R, Wulfkuhle J, Espina V, Aurajo R, Edmiston KH, Liotta LA, Petricoin EF 3rd. Development of reverse phase protein microarrays for clinical applications and patient-tailored therapy. *Cancer Genomics Proteomics.* 2007 May-Jun;4(3):157-64.
<http://cgp.iarjournals.org/content/4/3/157.long>

Rapkiewicz A, Espina V, Zujewski JA, Lebowitz PF, Filie A, Wulfkuhle J, Camphausen K, Petricoin EF 3rd, Liotta LA, Abati A. The needle in the haystack: Application of breast fine-needle aspirate samples to quantitative protein microarray technology. *Cancer Cytology.* 2007 Jun 25;111(3):173-84.
<https://doi.org/10.1002/cncr.22686>

VanMeter A, Calvert VS., Wulfkuhle JD., Petricoin EF, Liotta LA., Espina V. Qualification of Microarrayers for Clinical Research, BioRadiations. 2007. February 1.
http://www.bio-rad.com/webroot/web/pdf/lsl/literature/Bulletin_5534.pdf

Nijdam AJ, Ming-Cheng Cheng M, Geho DH, Fedele R, Herrmann P, Killian K, Espina V, Petricoin EF 3rd, Liotta LA, Ferrari M. Physicochemically modified silicon as a substrate for protein microarrays. *Biomaterials.* 2006 Sep 18 [Epub ahead of print]
<https://dx.doi.org/10.1021%2Fpr800455y>

Wu SL, Kim J, Bandle RW, Liotta L, Petricoin E, Karger BL. Dynamic profiling of the post-translational modifications and interaction partners of epidermal growth factor receptor signaling after stimulation by EGF using extended range proteomic analysis (ERPA). *Mol Cell Proteomics.* 2006 Jun 23; [Epub ahead of print]
<https://doi.org/10.1074/mcp.M600105-MCP200>

Wulfkuhle JD, Edmiston KH, Liotta LA, Petricoin EF. Technology Insight: pharmacoproteomics for cancer-promises of patient-tailored medicine using protein microarrays. *Nat Clin Pract Oncol.* 2006 May;3(5):256-68.
<https://doi.org/10.1038/ncponc0485>

Speer R, Wulfkuhle JD, Liotta LA. Petricoin EF. Reverse-phase protein microarrays for tissue-based analysis. *Curr Opin Mol Ther.* 2005 Jun;7(3):240-5.
<https://www.ncbi.nlm.nih.gov/pubmed/15977421>

Geho D, Lahar N, Gurnani P, Huebschman M, Herrmann P, Espina V, Shi A, Wulfkuhle J, Garner H, Petricoin E 3rd, Liotta LA, Rosenblatt KP. Pegylated, Steptavidin-Conjugated Quantum Dots Are Effective Detection Elements for Reverse-Phase Protein Microarrays. *Bioconjug Chem*. 2005 May 18;16(3):559-566.
<https://pubs.acs.org/doi/abs/10.1021/bc0497113>

Cowherd SM, Espina VA, Petricoin EF 3rd, Liotta LA. Proteomic analysis of human breast cancer tissue with laser-capture microdissection and reverse-phase protein microarrays. *Clin Breast Cancer*. 2004 Dec;5(5):385-92.

<https://doi.org/10.3816/CBC.2004.n.046>

Araujo RP, Doran C, Liotta L, Petricoin EF. Network targeted combination therapy: a new concept in cancer treatment. *Drug Discovery Today*. 2004 1(4)425-433.
<http://dx.doi.org/10.1016%2Fj.ddstr.2004.11.004>

Espina V, Woodhouse EC, Wulfkuhle J, Asmussen HD, Petricoin EF 3rd, Liotta LA. Protein microarray detection strategies: focus on direct detection technologies. *J Immunol Methods*. 2004 Jul;290(1-2):121-33.

<https://doi.org/10.1016/j.jim.2004.04.013>

Johann DJ Jr, McGuigan MD, Patel AR, Tomov S, Ross S, Conrads TP, Veenstra TD, Fishman DA, Whiteley GR, Petricoin EF 3rd, and Liotta LA. Clinical proteomics and biomarker discovery. *Ann N Y Acad Sci*. 2004 Jun;1022:295-305.
<https://doi.org/10.1196/annals.1318.045>

Petricoin E, Wulfkuhle J, Espina V, and Liotta LA. Clinical proteomics: Revolutionizing disease detection and patient tailoring therapy. *J Proteome Res*. 2004 Mar-Apr;3(2):209-17.

<https://pubs.acs.org/doi/abs/10.1021/pr049972m>

Calvert VS, Tang Y, Boveia V, Wulfkuhle J, Schutz-Geschwender Olive DM, Liotta LA, Petricoin EF Development of Multiplexed Protein Profiling and Detection Using Near Infrared Detection of Reverse-Phase Protein Microarrays Clinical Proteomics 2004 1(1) 81-90.

<https://link.springer.com/article/10.1385/CP:1:1:081>

Espina V, Petricoin EF, Liotta LA, Geho D Application of Sector Protein Microarrays to Clinical Samples Clinical Proteomics 2004 1(1) 91-100.

<https://core.ac.uk/download/pdf/81907634.pdf>

Hasan RK, Wulfkuhle JD, Liotta LA, and Petricoin EF. Molecular technologies for personalized cancer management. *JAMA*. 2004 Apr 7;291(13):1644-5.

<https://doi.org/10.1001/jama.291.13.1644>

Liotta LA, Espina V, Mehta AI, Calvert V, Rosenblatt K, Geho D, Munson PJ, Young L, Wulfkuhle J, and Petricoin EF. Protein microarrays: Meeting analytical challenges for clinical applications. *Cancer Cell*. 2003 Apr;3(4):317-25.

[https://doi.org/10.1016/S1535-6108\(03\)00086-2](https://doi.org/10.1016/S1535-6108(03)00086-2)

Petricoin, E.F., Zoon, K.C., Kohn, E.C., Barrett, J.C., and Liotta, L.A. Clinical proteomics: Translating benchside promise into bedside reality. *Nature Rev. Drug Disc.* 2002 Sep;1(9):683-95.

<https://home.ccr.cancer.gov/ncifdaproteomics/pdf/ClinicalProteomics.pdf>

Petricoin EF 3rd, Hackett JL, Lesko LJ, Puri RK, Gutman SI, Chumakov K, Woodcock J, Feigal DW Jr, Zoon KC, and Sistare FD. Medical applications of microarray technologies: A regulatory science perspective. *Nat Genet*. 2002 Dec;32 Suppl:474-9.
<https://doi.org/10.1038/ng1029>

Charboneau L, Scott H, Chen T, Winters M, Petricoin EF 3rd, Liotta LA, and Paweletz CP. Technique review: Utility of reverse phase protein arrays: Applications to signalling pathways and human body arrays. *Brief Funct Genomic Proteomic*. 2002 Oct;1(3):305-15.

<https://pdfs.semanticscholar.org/1154/8ee908ba0a7eda9b40cb1b6089e1a359bd70.pdf>

Liotta LA, Kohn EC, and Petricoin EF. Clinical proteomics: Personalized molecular medicine. *JAMA*. 2001 Nov 14;286(18):2211-4.

<https://jamanetwork.com/journals/jama/article-abstract/194350>